4SC AG | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
10,525.00
9,626.00
8,188.00
11,284.00
10,927.00
17,565
Depreciation, Depletion & Amortization
1,873.00
1,095.00
895.00
892.00
899.00
841
Other Funds
59.00
-
-
-
-
1,332
Funds from Operations
8,623.00
8,506.00
7,997.00
11,786.00
9,668.00
15,392
Changes in Working Capital
1,636.00
134.00
961.00
1,136.00
1,127.00
770
Net Operating Cash Flow
6,987.00
8,372.00
8,958.00
12,922.00
8,541.00
16,162
Capital Expenditures
120.00
103.00
223.00
464.00
172.00
Sale of Fixed Assets & Businesses
10.00
-
-
8.00
39.00
Purchase/Sale of Investments
4,979.00
1,000.00
1,318.00
800.00
-
Net Investing Cash Flow
4,869.00
897.00
1,541.00
2,994.00
133.00
Issuance/Reduction of Debt, Net
-
317.00
1,165.00
1,500.00
-
Net Financing Cash Flow
59.00
6,778.00
28,773.00
1,500.00
39,953.00
Net Change in Cash
2,177.00
697.00
18,274.00
11,428.00
31,279.00
Free Cash Flow
7,086.00
8,472.00
9,067.00
13,326.00
8,709.00
Other Sources
-
-
-
2,650.00
-
Change in Capital Stock
-
6,461.00
27,608.00
-
39,953.00

About 4SC

View Profile
Address
Fraunhoferstrasse 22
Planegg-Martinsried Bayern (Bavaria) 82152
Germany
Employees -
Website http://www.4sc.de
Updated 07/08/2019
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms. It also involves in the preclinical and clinical development of its products. Its assets are resminostat, 4SC-202, and 4SC-208.